Skip to main content

Grafa News and Videos — Page 1616

Latest

Grafa
Health

Connect Biopharma reports positive Phase 1 rademikibart data

Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.

Read more: Connect Biopharma reports positive Phase 1 rademikibart data
Grafa

United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis

United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.

Read more: United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis
Grafa

Neumora Therapeutics reports Q4 and FY financial results and clinical program updates

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biotechnology company pioneering precision medicines for brain diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Read more: Neumora Therapeutics reports Q4 and FY financial results and clinical program updates
Grafa
Health

China approves GSK’s Exdensur as first semi-annual treatment for severe asthma

GSK (NYSE:GSK) today announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype.

Read more: China approves GSK’s Exdensur as first semi-annual treatment for severe asthma
Grafa

Zymeworks receives FDA fast track designation for ZW191 in platinum-resistant ovarian cancer

Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).

Read more: Zymeworks receives FDA fast track designation for ZW191 in platinum-resistant ovarian cancer
Grafa
Energy

Leidos completes $2.4B acquisition of ENTRUST Solutions to bolster grid modernization

Leidos (NYSE:LDOS), a Fortune 500 innovation leader in defense, aviation, and information technology, announced today the successful completion of its acquisition of ENTRUST Solutions Group for approximately $2.4 billion.

Read more: Leidos completes $2.4B acquisition of ENTRUST Solutions to bolster grid modernization
Grafa
Health

IDEAYA Biosciences announces first patient dosed in Phase 1 IDE849 and IDE161 combination study

IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.

Read more: IDEAYA Biosciences announces first patient dosed in Phase 1 IDE849 and IDE161 combination study
Grafa

Nanobiotix lung cancer trial data shows 71% response rate at ELCC

NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches, today announced promising initial data from the Phase 2 CONVERGE study evaluating its lead candidate, JNJ-1900 (NBTXR3), in patients with stage 3 inoperable non-small cell lung cancer (NSCLC).

Read more: Nanobiotix lung cancer trial data shows 71% response rate at ELCC

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift